Keck Medicine of USC Initiates Early-Phase Stem Cell Trial for Parkinson's Disease
Keck Medicine of USC has initiated an early-phase clinical trial to evaluate a stem cell therapy for Parkinson's disease. The trial aims to assess the safety and potential effectiveness of implanting specialized stem cells into the brain to replace damaged cells and restore dopamine production. This multisite study, involving 12 participants with moderate to moderate-severe Parkinson's, utilizes induced pluripotent stem cells (iPSCs) developed by Kenai Therapeutics, and has received Fast Track designation from the U.S. Food & Drug Administration.
Keck Medicine of USC is leading an early-phase clinical trial to assess a groundbreaking stem cell therapy for Parkinson's disease, aiming to restore dopamine production with iPSC-derived cells. This innovative therapy, designated RNDP-001, has received Fast Track designation from the FDA.
Understanding Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disorder affecting over one million individuals in the United States, with approximately 90,000 new diagnoses annually. The condition is characterized by the gradual loss of dopamine-producing brain cells, which impacts the brain's ability to regulate movement. Dopamine is a neurotransmitter crucial for movement, memory, and mood.
This cellular loss leads to symptoms such as tremors, stiffness, and slow movement. Currently, available treatments manage symptoms but do not halt or slow the disease's progression.
The Clinical Trial: RNDP-001
Keck Medicine of USC is one of three U.S. organizations participating in a multi-site Phase 1 clinical trial. The study focuses on a new therapeutic approach involving the surgical implantation of specialized stem cells into the brain. These cells are programmed to replace lost neurons and produce dopamine.
Key Investigators
- Principal Investigator: Dr. Brian Lee, a neurosurgeon with Keck Medicine.
- Co-Principal Investigator: Dr. Xenos Mason, a neurologist specializing in Parkinson's disease.
Therapy Mechanism
The therapy utilizes induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed to an undifferentiated state. These iPSCs are intended to mature into dopamine-producing brain cells, with the goal of restarting the brain's normal dopamine production.
The stem cell therapy, designated RNDP-001, was developed by Kenai Therapeutics.
Dr. Lee has stated that restoring normal dopamine production in the brain could potentially slow the progression of Parkinson's disease and improve motor function.
Surgical Procedure and Monitoring
During the procedure, a small opening is created in the patient's skull to access the brain. Stem cells are then precisely implanted into the basal ganglia, a brain region involved in movement control, with guidance from magnetic resonance imaging (MRI).
Following the surgery, participants are monitored for a period of 12 to 15 months to observe changes in Parkinson's symptoms and identify any potential side effects, such as dyskinesia or infection. Long-term follow-up for patients is planned for up to five years.
Trial Scope and Objectives
The clinical trial involves a total of 12 participants who have been diagnosed with moderate to moderate-severe Parkinson's disease. The U.S. Food & Drug Administration has granted the Phase 1 REPLACE™ clinical trial Fast Track designation, which is intended to expedite its development and review process.
The overall objective of the research is to develop a technique capable of repairing patients' motor function and enhancing their quality of life.